Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06834009 · ClinicalTrials.gov registry record · Phase 1
A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT06834009 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 10 participants.
The verdict
NCT06834009, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the sensory attributes (basic tastes, aroma, texture, mouthfeel) of SUZ SDD and assess the impact of the dose on the sensory attributes.
Interventions
- DRUG SUZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2025-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06834009
The ClinicalTrials.gov registry entry for NCT06834009 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SUZ is the first listed.
NCT06834009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06834009 about?
NCT06834009 is a clinical study titled "A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists". The purpose of this study is to evaluate the sensory attributes (basic tastes, aroma, texture, mouthfeel) of SUZ SDD and assess the impact of the dose on the sensory attributes.
What is the current status of trial NCT06834009?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-03-10. Estimated completion is 2025-04-24.
What interventions are being tested in trial NCT06834009?
The interventions under investigation include: SUZ (DRUG).
Who is sponsoring clinical trial NCT06834009?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.